Compare ERII & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | PSNL |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.2M | 729.1M |
| IPO Year | 2008 | 2019 |
| Metric | ERII | PSNL |
|---|---|---|
| Price | $10.64 | $7.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $16.50 | $11.50 |
| AVG Volume (30 Days) | 600.4K | ★ 1.3M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.00 | ★ 33.58 |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $134,987,000.00 | $69,648,000.00 |
| Revenue This Year | $17.21 | $16.94 |
| Revenue Next Year | $21.97 | $36.58 |
| P/E Ratio | $25.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.59 | $2.83 |
| 52 Week High | $18.31 | $11.50 |
| Indicator | ERII | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 24.85 | 40.15 |
| Support Level | N/A | $7.37 |
| Resistance Level | $14.74 | $7.78 |
| Average True Range (ATR) | 0.57 | 0.72 |
| MACD | -0.53 | -0.02 |
| Stochastic Oscillator | 15.50 | 1.11 |
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.